{"groups":[{"description":"40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG000","title":"BT062 40 mg/m²"},{"description":"50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG001","title":"BT062 50 mg/m²"},{"description":"65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG002","title":"BT062 65 mg/m²"},{"description":"80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG003","title":"BT062 80 mg/m²"},{"description":"100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG004","title":"BT062 100 mg/m²"},{"description":"120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG005","title":"BT062 120 mg/m²"},{"description":"140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG006","title":"BT062 140 mg/m²"},{"description":"160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"FG007","title":"BT062 160 mg/m²"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The Intention-to-treat (ITT) population included all subjects who were enrolled in the study and received at least 1 dose of BT062 and who had any post-Baseline evaluations or data. One subject did not have at least one post-injection assessment of the treatment response and was excluded from both the ITT and PP populations (n = 34)."}